Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Account Payables (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Change in Account Payables for 11 consecutive years, with -$40564.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 110.55% year-over-year to -$40564.0, compared with a TTM value of $244152.0 through Sep 2025, down 50.34%, and an annual FY2024 reading of $226119.0, up 127.98% over the prior year.
  • Change in Account Payables was -$40564.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$662048.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.2 million in Q1 2025 and bottomed at -$662048.0 in Q2 2025.
  • Average Change in Account Payables over 5 years is -$17619.1, with a median of -$12776.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables soared 2461.65% in 2024, then tumbled 1030.78% in 2025.
  • Year by year, Change in Account Payables stood at -$300790.0 in 2021, then surged by 147.09% to $141641.0 in 2022, then tumbled by 71.31% to $40635.0 in 2023, then crashed by 653.37% to -$224863.0 in 2024, then skyrocketed by 81.96% to -$40564.0 in 2025.
  • Business Quant data shows Change in Account Payables for KPRX at -$40564.0 in Q3 2025, -$662048.0 in Q2 2025, and $1.2 million in Q1 2025.